DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $48,806,728 | +5.9% | 196,722 | +2.4% | 0.54% | +9.9% |
| Q2 2023 | $46,109,280 | -4.7% | 192,122 | +0.1% | 0.50% | -12.7% |
| Q1 2023 | $48,372,021 | +0.9% | 191,922 | +6.3% | 0.57% | +5.0% |
| Q4 2022 | $47,940,691 | +20.8% | 180,622 | +17.6% | 0.54% | +11.3% |
| Q3 2022 | $39,679,000 | +1.2% | 153,622 | -0.7% | 0.49% | -4.7% |
| Q2 2022 | $39,225,000 | -11.7% | 154,722 | +2.2% | 0.51% | +1.0% |
| Q1 2022 | $44,417,000 | -6.7% | 151,422 | +4.7% | 0.50% | +5.2% |
| Q4 2021 | $47,582,000 | +11.6% | 144,622 | +3.3% | 0.48% | -0.6% |
| Q3 2021 | $42,628,000 | -34.3% | 140,022 | -46.3% | 0.48% | +16.4% |
| Q2 2021 | $64,847,000 | +144.5% | 260,644 | +121.2% | 0.42% | +11.9% |
| Q1 2021 | $26,519,000 | +8.6% | 117,822 | +7.2% | 0.37% | +0.8% |
| Q4 2020 | $24,418,000 | +38.1% | 109,922 | +33.9% | 0.37% | +0.8% |
| Q3 2020 | $17,683,000 | -7.5% | 82,122 | -24.0% | 0.36% | -27.4% |
| Q2 2020 | $19,107,000 | +37.4% | 108,053 | +7.6% | 0.50% | +0.8% |
| Q1 2020 | $13,904,000 | -66.6% | 100,453 | -63.0% | 0.50% | -76.0% |
| Q4 2019 | $41,678,000 | -14.5% | 271,553 | -19.5% | 2.08% | +2.1% |
| Q3 2019 | $48,734,000 | +0.6% | 337,422 | -0.5% | 2.03% | -6.7% |
| Q2 2019 | $48,467,000 | +6.9% | 339,122 | -1.2% | 2.18% | +9.1% |
| Q1 2019 | $45,325,000 | +52.4% | 343,322 | +19.0% | 2.00% | +41.1% |
| Q4 2018 | $29,742,000 | -4.0% | 288,422 | +1.1% | 1.42% | +13.8% |
| Q3 2018 | $30,985,000 | -15.7% | 285,158 | -23.4% | 1.24% | -10.1% |
| Q2 2018 | $36,734,000 | -7.1% | 372,258 | -7.8% | 1.38% | +1.0% |
| Q1 2018 | $39,552,000 | +4.7% | 403,958 | -0.7% | 1.37% | -0.5% |
| Q4 2017 | $37,774,000 | +3.6% | 406,958 | -4.2% | 1.38% | +7.1% |
| Q3 2017 | $36,453,000 | -18.7% | 424,958 | -20.0% | 1.28% | +2.5% |
| Q2 2017 | $44,830,000 | -10.7% | 531,224 | -9.5% | 1.25% | -22.2% |
| Q1 2017 | $50,208,000 | -1.3% | 587,024 | -10.2% | 1.61% | -1.5% |
| Q4 2016 | $50,863,000 | -23.9% | 653,436 | -23.4% | 1.64% | -12.1% |
| Q3 2016 | $66,877,000 | -27.6% | 853,136 | -6.7% | 1.86% | -30.6% |
| Q2 2016 | $92,380,000 | +117.2% | 914,658 | +45.8% | 2.68% | +97.4% |
| Q4 2015 | $42,529,000 | – | 627,311 | – | 1.36% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |